ALX Oncology Q3 2021 Earnings Report
Key Takeaways
ALX Oncology reported its Q3 2021 financial results, highlighting the advancement of its lead program, evorpacept (ALX148), through multiple clinical trials, including new data from the ASPEN-01 trial presented at the ESMO conference and the dosing of the first patient in the ASPEN-04 trial. The company also acquired ScalmiBio, expanding its immuno-oncology pipeline.
Reported new data at the ESMO conference from ASPEN-01, a Phase 1b trial testing evorpacept with trastuzumab, ramucirumab and paclitaxel in >2nd line HER2-positive gastric or gastroesophageal junction cancer.
Dosed the first patient in ASPEN-04, a Phase 2 trial testing evorpacept in combination with pembrolizumab and chemotherapy for 1st line patients with unresectable or metastatic squamous cell carcinoma of the head and neck.
Subsequent to the quarter end, dosed the first patients in ASPEN-05 Phase 1/2 study in acute myeloid leukemia and in a Phase 1/2 collaboration with Zymeworks.
Acquired privately-held ScalmiBio, gaining full access to their proprietary SHIELD platform.
ALX Oncology
ALX Oncology
Forward Guidance
ALX Oncology expects a data-filled fourth quarter.
Positive Outlook
- Four poster presentations at the upcoming SITC conference, including data from ASPEN-01.
- Trial designs from both Phase 2 head and neck cancer studies in collaboration with Merck (ASPEN-03 and ASPEN-04).
- Preclinical data for ALTA-002, a first in class SIRPa-directed TLR9 agonist antibody conjugate being developed in collaboration with Tallac Therapeutics.
- Report additional Phase 1b data from ASPEN-02 in myelodysplastic syndromes.
- Initiation of ASPEN-06, a randomized Phase 2 trial in second line gastric cancer